Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2014-A00309-38 | Other Identifier | ANSM |
Not provided
Not provided
lack of inclusion
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease which involves respiratory muscles and can lead at short term to respiratory failure. The occurrence of respiratory failure is associated with morbidity and an increased mortality. To date, respiratory muscle weakness is predicted from the reduction of vital capacity, maximal inspiratory force, nocturnal symptoms and hypercapnia. Even taken together, the predictive value of these indices is low.
The investigators hypothesize that an endurance test of diaphragmatic work would be more sensitive to respiratory muscle involvement than maximal respiratory force.
Consequently, the investigators assessed diaphragmatic performance through an isocapnic hyperventilation test (IHT) in patients at the onset of ALS and, then regularly up to the occurrence of respiratory failure. The investigators make the hypothesis that IHT will be altered earlier than maximal inspiratory force
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients | ALS patients performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity at the onset of the disease and repeated every 3 months up to respiratory failure or death |
| |
| Control | Healthy controls performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity. This arm will enable to establish reference values of IHT |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Diaphragmatic endurance test | Other | This consists of hyperventilation in a flask while maintaining the constant level of Carbon Dioxide (CO2). The patient will realize hyperventilation to increasing levels of Maximum Minute Ventilation (MMV), corresponding to increasing levels of respiratory rate, until exhaustion |
| Measure | Description | Time Frame |
|---|---|---|
| Endurance time | Difference in endurance time during the IHT between healthy controls and ALS patients when diagnosis is established | Day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Reference values of the diaphragmatic endurance test | Reference values of the diaphragmatic endurance test in healthy controls according to age, by 10 years range. | Day 1 |
| Reference values of phrenic nerve activity |
Not provided
Inclusion Criteria for Patients :
Inclusion Criteria for control group :
Exclusion Criteria for Patients :
Exclusion Criteria for control group :
Not provided
Not provided
Patients with ALS Healthly volonteers
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Frederic COSTES, MD PhD | University Hospital, Clermont-Ferrand | Study Chair |
| Isabelle COURT-FORTUNE, MD | CHU de Saint-Etienne | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de SAINT-ETIENNE | Saint-Etienne | 42000 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000690 | Amyotrophic Lateral Sclerosis |
| ID | Term |
|---|---|
| D013118 | Spinal Cord Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D016472 | Motor Neuron Disease |
Not provided
Not provided
Not provided
Not provided
Not provided
|
Reference values of phrenic nerve activity in healthy controls according to age. It is measured with diaphragmatic Electromyogram by cervical electrical stimulation.
| Day 1 |
| Slope of endurance time decrease | Slope of endurance time decrease with time in ALS patients measured during IHT | At Day 1 and every 3 months of follow-up (3 years) |
| Amplitude of phrenic nerve | It is the relationship between phrenic nerve activity and diaphragmatic endurance in ALS patients | At Day 1 and every 3 months of follow-up (3 years) |
| Latency of phrenic nerve | It is the relationship between phrenic nerve activity and diaphragmatic endurance in ALS patients | At Day 1 and every 3 months of follow-up (3 years) |
| D019636 | Neurodegenerative Diseases |
| D057177 | TDP-43 Proteinopathies |
| D009468 | Neuromuscular Diseases |
| D057165 | Proteostasis Deficiencies |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |